Ramesh Bansal, MD
Adult Congenital Heart Disease · Loma Linda, CANPI 1508884388
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,442 of the $2,360 with a category attached, or 61.1%. Abbott accounts for 66.4% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $1,296 and has fallen 58.6% since, to $536 in 2025.
Across 32 payments — averaging $73.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Edwards Lifesciences$541
- E.r. Squibb & Sons, L.L.C.$77
- Philips North America LLC$62
- Biosense Webster, Inc.$55
- Shockwave Medical, Inc$24
- plus $34 from 2 others
What the payments were for
- Travel & lodging$91839%
- Food & beverage$1,44261%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 13 | $1,567 |
| Edwards Lifesciences | 8 | $541 |
| E.r. Squibb & Sons, L.L.C. | 4 | $77 |
| Philips North America LLC | 3 | $62 |
| Biosense Webster, Inc. | 1 | $55 |
| Shockwave Medical, Inc | 1 | $24 |
| Boston Scientific | 1 | $17 |
| Irhythm Technologies, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MitraClip$1,024
- Mitra Clip system$138
How this compares
Too few adult congenital heart disease providers in Californiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Losartan Potassium | 54 | $601 |
| Metoprolol Succinate | 29 | $543 |
| Potassium Chloride | 25 | $405 |
| Warfarin Sodium | 46 | $405 |
| Atenolol | 25 | $402 |
| Digoxin | 14 | $296 |
| Atorvastatin Calcium | 28 | $184 |
| SotalolSotalol Hcl | 11 | $170 |
| Hydrochlorothiazide | 30 | $119 |
| Furosemide | 28 | $113 |
| Metoprolol Tartrate | 13 | $69 |
| Spironolactone | 11 | $52 |
| Benazepril Hcl | 11 | $8 |
Paid to pharmacies, not to this prescriber.
Other adult congenital heart disease in Loma Linda
- Ahmed KheiwaLoma Linda$5K
- Taylor HolveSanta Barbara$15K
- Angela LiOrange$8K
- Priya PillutlaLos Angeles$4K
- Prashanth VenkateshLos Angeles$3K
- Padmini VaradarajanRedlands$1K
- Karen SchultzSacramento$825
- Jeannette LinOrange$569
- Daniel ClarkStanford$311
- George LuiStanford$286
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.